November 22nd 2024
A phase 1 trial of α-lactalbumin vaccine for the treatment of patients with triple-negative breast cancer demonstrated safety and tolerability.
November 21st 2024
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
Empowering Breast Cancer Patients with Non-Opioid Pain Management Innovations
View More
Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connection™: Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
How We Do It™: Defining HER2 Low on Your Pathology Reports to Make Informed Decisions in Breast Cancer Treatment
View More
Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
24th Annual International Congress on the Future of Breast Cancer® West
July 18-19, 2025
Register Now!
24th Annual International Congress on the Future of Breast Cancer® East
July 11-12, 2025
Register Now!
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West
View More
School of Breast Oncology® (SOBO) Slide & Lecture Library
Joyce O’Shaughnessy, MD
View More
Trastuzumab Deruxtecan Receives Accelerated Approval by FDA for HER2+ Breast Cancer
December 21st 2019Fam-trastuzumab deruxtecan-nxki has been granted an accelerated approval by the FDA for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received at least 2 prior lines of anti–HER2-based regimens in the metastatic setting.
Read More
Margetuximab Developer Seeks FDA Approval for the Treatment of Metastatic HER+ Breast Cancer
December 20th 2019A biologics license application has been submitted to the FDA for margetuximab in combination with chemotherapy for the treatment of patients with metastatic HER2-positive breast cancer, according to a press release from MacroGenics, Inc.<br />
Read More
The FDA has granted Breakthrough Therapy Designation to the addition of tucatinib to trastuzumab and capecitabine for the treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases who received prior treatment with trastuzumab, pertuzumab, and T-DM1, according to a press release from Seattle Genetics.<br />
Read More
The TBCRC049 Trial for Treating Leptomeningeal Metastases in HER2+ Breast Cancer
December 14th 2019Adam M. Brufsky, MD, PhD, FACP, discusses the TBCRC049 trial, which looks at the safety and efficacy of the tucatinib/trastuzumab/capecitabine combination to treat leptomeningeal metastases in HER2-positive breast cancer.
Watch
Durvalumab Regimen Shows Promise for Treatment of TNBC in the Neoadjuvant Setting
December 13th 2019A pathologic complete response rate of 44% was observed with a neoadjuvant durvalumab (Imfinzi)-based regimen administered to patients with triple-negative breast cancer, according to results of a phase I/II study presented in a poster at the 2019 San Antonio Breast Cancer Symposium.
Read More
The monarcHER Trial in Advanced HR+, HER2+ Breast Cancer
December 13th 2019Sara M. Tolaney, MD, MPH, discusses the results of the monarcHER trial, which examined adding the CDK4/6 inhibitor abemaciclib and endocrine therapy to trastuzumab versus trastuzumab plus chemotherapy in advanced hormone receptor-positive, HER2-positive breast cancer.
Watch
Preventative Breast Cancer Effect Maintained With Anastrozole in Long-Term Follow-Up Data
December 13th 2019Nearly 12 years after discontinuing treatment, anastrozole, an aromatase inhibitor, maintained a preventive effect for postmenopausal women at high risk for breast cancer. Women assigned to anastrozole were 49% less likely to have developed breast cancer compared with women assigned to placebom according to data presented at the 2019 San Antonio Breast Cancer Symposium.
Read More
Addition of Atezolizumab Did Not Statistically Improve pCR in Triple-Negative Breast Cancer
December 13th 2019Preliminary results from the phase III NeoTRIPaPDL1 Michelangelo study showed that the addition of atezolizumab to combination carboplatin plus nab-paclitaxel did not result in a statistically significant increase in the pathologic complete response rate compared with the combination alone in patients with early high-risk and locally advanced triple-negative breast cancer.
Read More
Risk of Recurrence Reduced With Dual Anti-HER2 Therapy in Breast Cancer
December 13th 2019According to a pooled analysis of neoadjuvant trials presented at the San Antonio Breast Cancer Symposium, a pathologic complete response to HER2-directed neoadjuvant therapy reduced the risk of recurrence in patients with early HER2-positive breast cancer but did not eliminate it, supporting the common practice of continued anti-HER2 therapy.
Read More
Durvalumab Maintenance May Improve Outcomes in Triple-Negative Breast Cancer
December 13th 2019In patients with triple-negative breast cancer or those with PD-L1–positive breast cancer across several subtypes, durvalumab as maintenance therapy, may improve outcomes compared with chemotherapy, according to an exploratory analyses from the phase II randomized SAFIR02-IMMUNO trial presented at the 2019 San Antonio Breast Cancer Symposium.
Read More
Pathologic Complete Response Rates in TNBC Benefit From the Addition of Pembrolizumab
December 12th 2019The addition of pembrolizumab to standard-of-care chemotherapy for neoadjuvant and adjuvant treatment of early triple-negative breast cancer lead to higher rates of pathologic complete responses in the KEYNOTE-522 trial, especially in those patients with stage III and/or node-positive disease.
Read More
Palbociclib Real-World Data Hint OS Benefit in Frontline HR+/HER2- Breast Cancer
December 12th 2019Frontline treatment with palbociclib demonstrated positive progression-free survival n real-world patients with HR-positive/HER2-negative metastatic breast cancer and may lead to an overall survival benefit , according to data from the pivotal PALOMA-2 trial.
Read More
Adjuvant T-DM1 Leads to Low Recurrence Rates in Patients With Early HER2+ Breast Cancer
December 12th 2019High rates of disease control were reported in the first set of results from a randomized trial in which adjuvant T-DM1 was compared to trastuzumab and paclitaxel for the treatment of patients with early HER2-positive breast cancer.
Read More
Margetuximab Shows Clinical Benefit Over Trastuzumab in HER2+ Metastatic Breast Cancer
December 12th 2019Patients with HER2-positive metastatic breast cancer who had received prior anti-HER2 therapies continued to experience a progression-free survival benefit with margetuximab and a trend toward overall survival compared with trastuzumab when either agent was combined with chemotherapy, according to updated findings from the phase III SOPHIA trial.
Read More
Adjuvant Pertuzumab Regimen Improves OS in Patients With HER2+ Early Breast Cancer
December 12th 2019In the phase III APHINITY trial, pertuzumab with trastuzumab plus chemotherapy demonstrated a 0.9% improvement in overall survival and continued to reduce the risk of disease recurrence in patients with HER2-positive early breast cancer in the adjuvant setting, according to a 6-year analysis of the phase III APHINITY trial presented at the 2019 San Antonio Breast Cancer Symposium.
Read More
Tucatinib Demonstrates Survival Benefit in HER2+ Breast Cancer, FDA Submission Impending
December 12th 2019In the phase II HER2CLIMB trial, a 34% reduction in the risk of death was observed with the addition of tucatinib to the combination of trastuzumab and capecitabine in patients with heavily pretreated unresectable locally advanced or metastatic HER2-positive breast cancer compared to the combination alone, according to results from the phase II HER2CLIMB trial presented at the 2019 San Antonio Breast Cancer Symposium.
Read More
S-1 Shows Significant Improvement in iDFS for HR+, HER2-Breast Cancer
December 12th 2019Japanese patients with HR-positive, HER2-negative breast cancer had a significant improvement in invasive disease-free survival with the addition of the novel oral fluoropyrimidine derivative S-1, according to findings from the phase III POTENT trial presented at the 2019 San Antonio Breast Cancer Symposium.
Read More
Responses Observed With T-DXd May Change Standard of Care in Advanced HER2+ Breast Cancer
December 11th 2019In heavily pretreated patients with advanced HER2-positive breast cancer, trastuzumab deruxtecan induced a confirmed objective response rate of almost 61% and a durable benefit, according to results from the phase II DESTINY-Breast01 trial presented at the 2019 San Antonio Breast Cancer Symposium.
Read More
Continuing the Overall Survival Analysis in the MONARCH-2 Trial
December 3rd 2019George W. Sledge, Jr., MD, professor of medicine, Stanford University Medical Center, discusses the next steps for the phase III MONARH-2 trail following the positive interim analysis results presented during the 2019 European Society of Medical Oncology Congress.
Watch